Cargando…

Dual Anti-Glomerular Basement Membrane and Anti-Neutrophil Cytoplasmic Antibodies—Positive Rapidly Progressive Glomerulonephritis with Rheumatoid Arthritis and Sjogren’s Syndrome: A Case Report and Literature Review

Rapidly progressive glomerulonephritis (RPGN) is a life-threatening disease characterized by rapid progressive deterioration of renal function and extensive formation of crescents. Some antibodies tend to be positive, such as a perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) and anti-glome...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Ting, Zhi, Huiwen, Liu, Yunxiao, Zhang, Shengxiao, Song, Ziyi, Li, Yafeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697768/
https://www.ncbi.nlm.nih.gov/pubmed/36431270
http://dx.doi.org/10.3390/jcm11226793
Descripción
Sumario:Rapidly progressive glomerulonephritis (RPGN) is a life-threatening disease characterized by rapid progressive deterioration of renal function and extensive formation of crescents. Some antibodies tend to be positive, such as a perinuclear anti-neutrophil cytoplasmic antibody (p-ANCA) and anti-glomerular basement membrane (anti-GBM) antibodies, in most patients with the disease. However, cases of double positivity for the above antibodies are considered to be rare. In addition, both rheumatoid arthritis (RA) and Sjogren’s syndrome (SS) are deemed to be independent immune disorders that can cause renal impairment. Nevertheless, the association between RPGN and these two diseases has not been elucidated in previous studies. Here, we provide a case of RPGN with the concurrence of RA and SS characterized by double positivity in anti-GBM antibodies and p-ANCA. After aggressive treatment with cyclophosphamide, glucocorticoids, and plasma exchange, the patient improved significantly. Despite the malignant event of arteriovenous fistula rupture and bleeding during treatment, the patient survived with renal function recovery for the rest of the follow-up period.